Savara (NASDAQ:SVRA) Trading Up 5.4%

Savara Inc (NASDAQ:SVRA) was up 5.4% on Wednesday . The stock traded as high as $4.72 and last traded at $4.70. Approximately 375,870 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 1,242,435 shares. The stock had previously closed at $4.46.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SVRA shares. Oppenheimer increased their price objective on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. Evercore ISI cut their price objective on shares of Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, May 16th. Guggenheim upped their target price on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of Savara in a research note on Monday, May 6th. Finally, HC Wainwright upped their target price on shares of Savara from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Savara presently has an average rating of “Buy” and an average target price of $11.00.

Savara Price Performance

The company’s 50-day moving average price is $4.28 and its 200-day moving average price is $4.64. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. The company has a market cap of $623.23 million, a P/E ratio of -12.76 and a beta of 1.00.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, sell-side analysts predict that Savara Inc will post -0.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Several large investors have recently made changes to their positions in SVRA. Vanguard Group Inc. increased its position in shares of Savara by 15.9% during the third quarter. Vanguard Group Inc. now owns 5,764,601 shares of the company’s stock worth $21,790,000 after acquiring an additional 789,249 shares in the last quarter. SG Americas Securities LLC boosted its holdings in Savara by 34.2% during the fourth quarter. SG Americas Securities LLC now owns 49,862 shares of the company’s stock worth $234,000 after purchasing an additional 12,720 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Savara during the fourth quarter worth $74,000. Jennison Associates LLC boosted its holdings in Savara by 128.0% during the fourth quarter. Jennison Associates LLC now owns 8,815,358 shares of the company’s stock worth $41,432,000 after purchasing an additional 4,948,596 shares during the last quarter. Finally, AJOVista LLC acquired a new position in Savara during the fourth quarter worth $40,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.